Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 2, 2026, 7:56 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 111 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Psychoses, Substance-Induced Clear all
Completed Not applicable Interventional

Contingency Management of Psychostimulant Abuse in the Severely Mentally Ill

NCT00809770
View directory record Official record
Conditions
Drug Abuse, Schizophrenia, Bipolar Disorder, Major Depressive Disorder
Interventions
Contingency Management, Non Contingent Control Condition
Behavioral
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 65 Years
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 8, 2016 · Synced Oct 2, 2026, 7:56 AM EDT
Completed Phase 4 Interventional

Improving Substance Use and Clinical Outcomes in Heavy Cannabis Users With Quetiapine

NCT01153490
View directory record Official record
Conditions
Cannabis Dependence
Interventions
Behavioral Intervention
Behavioral
Lead sponsor
Northwell Health
Other
Eligibility
18 Years to 65 Years
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
2
States / cities
Glen Oaks, New York • Manhasset, New York
Source: ClinicalTrials.gov public record
Updated Apr 17, 2018 · Synced Oct 2, 2026, 7:56 AM EDT
Terminated Not applicable Interventional

Contingency Management for Smoking Cessation Among Veterans With Psychotic Disorders

NCT00508560
View directory record Official record
Conditions
Nicotine Dependence, Psychotic Disorders
Interventions
Contingency Management, Reward
Behavioral
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 26, 2015 · Synced Oct 2, 2026, 7:56 AM EDT
Completed Phase 4 Interventional Results available

Risperidone Long-acting Versus Oral Risperidone in Patients With Schizophrenia and Alcohol Use Disorder

NCT00130923
View directory record Official record
Conditions
Schizophrenia, Psychotic Disorders, Substance Abuse, Alcohol Abuse
Interventions
Risperidone Long Acting, oral risperidone
Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
8
States / cities
Miami, Florida • Kansas City, Missouri • St Louis, Missouri + 5 more
Source: ClinicalTrials.gov public record
Updated May 9, 2019 · Synced Oct 2, 2026, 7:56 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Effectiveness of the Screen, Test, Immunize, Reduce Risk, and Refer (STIRR) Intervention for People With Both a Mental and Substance Abuse Disorder

NCT00316303
View directory record Official record
Conditions
HIV Infections, Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Depression, Substance Abuse
Interventions
Twinrix, Enhanced treatment as usual
Drug · Behavioral
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
236 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2012
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 22, 2013 · Synced Oct 2, 2026, 7:56 AM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

Cannabinoids, Learning, and Memory

NCT02407808
View directory record Official record
Conditions
Cannabis, Psychotic Disorders
Interventions
THC, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 55 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2027
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Oct 2, 2026, 7:56 AM EDT
Recruiting Phase 2 Interventional

GLP-1R Agonist Treatment for Opioid Use Disorder

NCT06548490
View directory record Official record
Conditions
Opioid Use Disorder, Opioid Abuse and Addiction, Narcotic-Related Disorders, Substance-Related Disorders, Chemically-Induced Disorders, Mental Disorder, Opioid
Interventions
Semaglutide Pen Injector, Placebo
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
4
States / cities
Baltimore, Maryland • Fall River, Massachusetts • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Oct 2, 2026, 7:56 AM EDT
Completed Phase 3 Interventional Results available

Treatment With Acamprosate in Patients With Schizophrenia and Comorbid Alcoholism

NCT00463346
View directory record Official record
Conditions
Alcohol Dependence, Schizophrenia
Interventions
Acamprosate, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
21 Years to 65 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2015
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 31, 2020 · Synced Oct 2, 2026, 7:56 AM EDT
Completed Phase 3 Interventional Results available

Aripiprazole for Bipolar Disorder and Alcohol Use Disorder

NCT02918370
View directory record Official record
Conditions
Bipolar Disorder, Alcoholism, Alcohol Abuse
Interventions
Aripiprazole, Placebo
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 2, 2026, 7:56 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Abilify Therapy for Reducing Comorbid Substance Abuse

NCT00208169
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Major Depressive Disorder, Anxiety Disorders, Substance Abuse
Interventions
Aripiprazole
Drug
Lead sponsor
Creighton University
Other
Eligibility
19 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Aug 24, 2007 · Synced Oct 2, 2026, 7:56 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Effects of Delta-9-THC and Iomazenil in Healthy Humans

NCT00982982
View directory record Official record
Conditions
Schizophrenia, Mental Disorders, Psychotic Disorders
Interventions
THC and Iomazenil, Placebo (control)
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 55 Years · Male only
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2013
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Dec 5, 2022 · Synced Oct 2, 2026, 7:56 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Nicotine and Cotinine Levels in Smokers With Schizophrenia and Schizoaffective Disorder - 2

NCT00135772
View directory record Official record
Conditions
Schizophrenia and Disorders With Psychotic Features, Tobacco Use Disorder
Interventions
Not listed
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 70 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2004
U.S. locations
1
States / cities
Piscataway, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 12, 2017 · Synced Oct 2, 2026, 7:56 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning

NCT01730781
View directory record Official record
Conditions
Schizophrenia, Cannabis Dependence, Prodromal for Psychotic Illness, Family History of Alcoholism, Healthy Control, Opioid-use Disorder, Post Traumatic Stress Disorder
Interventions
[11-C]OMAR
Radiation
Lead sponsor
Yale University
Other
Eligibility
18 Years to 55 Years · Male only
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2026
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Oct 2, 2026, 7:56 AM EDT
Completed Phase 4 Interventional Results available

Clozapine for Cannabis Use in Schizophrenia

NCT01639872
View directory record Official record
Conditions
Schizophrenia, Cannabis Abuse, Cannabis Dependence, Dual Diagnosis
Interventions
Clozapine, Risperidone
Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years to 55 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
9
States / cities
Garden Grove, California • Oakland, California • Miami, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated May 5, 2020 · Synced Oct 2, 2026, 7:56 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Effects of Nicotine on Areas of Impaired and Preserved Functioning in Schizophrenia

NCT01034085
View directory record Official record
Conditions
Nicotine Dependence, Schizophrenia
Interventions
Not listed
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 55 Years
Enrollment
62 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2013
U.S. locations
1
States / cities
Catonsville, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 5, 2018 · Synced Oct 2, 2026, 7:56 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Cannabis and Schizophrenia: Self-Medication and Agonist Treatment

NCT00946348
View directory record Official record
Conditions
Schizophrenia, Dual Diagnosis, Schizoaffective Disorder, Psychotic Disorder, Cannabis Use Disorder
Interventions
Dronabinol, Cannabis
Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years to 50 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Jul 12, 2021 · Synced Oct 2, 2026, 7:56 AM EDT
Completed Phase 2 Interventional Results available

Facilitation of NMDA Receptor Function in Patients With Schizophrenia and Co-morbid Alcoholism

NCT00338598
View directory record Official record
Conditions
Alcoholism, Schizophrenia
Interventions
Glycine, placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
21 Years to 60 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2015
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 17, 2018 · Synced Oct 2, 2026, 7:56 AM EDT
Completed Phase 4 Interventional

Injectable Naltrexone Treatment of Alcohol Dependence in Serious Mental Illness (SMI)

NCT00453609
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Alcohol Dependence
Interventions
long-lasting injectable naltrexone
Drug
Lead sponsor
State University of New York - Upstate Medical University
Other
Eligibility
18 Years to 69 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
3
States / cities
Syracuse, New York
Source: ClinicalTrials.gov public record
Updated Dec 11, 2008 · Synced Oct 2, 2026, 7:56 AM EDT
Completed Phase 4 Interventional

Naltrexone Treatment of Alcohol Abuse in Schizophrenia

NCT00145847
View directory record Official record
Conditions
Schizophrenia, Mental Disorders, Alcohol Abuse, Alcoholism, Alcohol-related Disorders
Interventions
Naltrexone or Placebo
Drug
Lead sponsor
State University of New York - Upstate Medical University
Other
Eligibility
18 Years to 69 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
4
States / cities
Syracuse, New York
Source: ClinicalTrials.gov public record
Updated Jan 8, 2013 · Synced Oct 2, 2026, 7:56 AM EDT
Completed Not applicable Interventional Results available

First Episode Schizophrenia and Cannabis-Related Disorder Study

NCT00573287
View directory record Official record
Conditions
Cannabis-Related Disorder, Substance-Related Disorders, Schizophrenia, Psychotic Disorders
Interventions
clozapine, risperidone
Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
17 Years to 45 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
5
States / cities
Concord, New Hampshire • Lebanon, New Hampshire • Manchester, New Hampshire + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2019 · Synced Oct 2, 2026, 7:56 AM EDT
Terminated Phase 4 Interventional

Extended Duration Nicotine Replacement Therapy and Bupropion in Smokers With Schizophrenia

NCT01576640
View directory record Official record
Conditions
Nicotine Dependence, Schizophrenia
Interventions
NRT, Bupropion SR 150mg bid, Relapse Prevention-Oriented Cognitive Behavioral Therapy
Drug · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 21, 2015 · Synced Oct 2, 2026, 7:56 AM EDT
Completed Not applicable Interventional Results available

Contingency Management of Alcohol Abuse in the Severely Mentally ILL

NCT01567943
View directory record Official record
Conditions
Alcohol Abuse, Schizophrenia, Bipolar Disorder, Major Depressive Disorder
Interventions
Contingency Management
Behavioral
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 65 Years
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Feb 23, 2017 · Synced Oct 2, 2026, 7:56 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Cannabinoids and Cerebellar-Motor Functioning

NCT01853020
View directory record Official record
Conditions
Cannabis, Psychotic Disorders
Interventions
THC, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
21 Years to 35 Years
Enrollment
57 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 2, 2026, 7:56 AM EDT
Withdrawn Phase 4 Interventional

Treating Schizophrenic Smokers: Effects on Craving, Cues and Withdrawal

NCT00781755
View directory record Official record
Conditions
Tobacco Use Disorder
Interventions
varenicline, Adaptation of Motivational Interviewing
Drug · Behavioral
Lead sponsor
VA Boston Healthcare System
Federal
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Brockton, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 4, 2015 · Synced Oct 2, 2026, 7:56 AM EDT